How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

196 results for

Dexon

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Dexon

Dexon Dexon Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dexon Dexon Aka: Dexon , Polyglycolic Acid Suture II. Category First (...) synthetic (1970) III. See Also IV. Indications Subcutaneous and intraoral closure V. Background: Absorption (Hydrolysis) Tensile and knot strength roughly equivalent to Day 7: 60% of tensile strength retained Day 15: 20% of tensile strength Day 28: 5% of tensile strength Day 90 to 120: completely absorbed VI. Preparations Monofilament Stiff, and difficult to handle Braided Dexon Easier to handle Dexon Plus (synthetic coat) Eases knot tying and tissue passage VII. References Epperson in Pfenninger

2018 FP Notebook

2. Dexon

Dexon Dexon Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Dexon Dexon Aka: Dexon , Polyglycolic Acid Suture II. Category First (...) synthetic (1970) III. See Also IV. Indications Subcutaneous and intraoral closure V. Background: Absorption (Hydrolysis) Tensile and knot strength roughly equivalent to Day 7: 60% of tensile strength retained Day 15: 20% of tensile strength Day 28: 5% of tensile strength Day 90 to 120: completely absorbed VI. Preparations Monofilament Stiff, and difficult to handle Braided Dexon Easier to handle Dexon Plus (synthetic coat) Eases knot tying and tissue passage VII. References Epperson in Pfenninger

2015 FP Notebook

3. Conversion of Dexon (p-Dimethylaminobenzenediazo Sodium Sulfonate) to N,N-Dimethyl-p-Phenylenediamine by Pseudomonas fragi Bk9 Full Text available with Trip Pro

Conversion of Dexon (p-Dimethylaminobenzenediazo Sodium Sulfonate) to N,N-Dimethyl-p-Phenylenediamine by Pseudomonas fragi Bk9 The metabolism of the fungicide Dexon (p-dimethylaminobenzenediazo sodium sulfonate) by a soil bacterium is reported for the first time. The organism which is capable of using Dexon only by a co-metabolic process was obtained by enrichment culture and was identified as Pseudomonas fragi. The first metabolic product of Dexon was identified as N,N-dimethyl-p (...) -phenylenediamine. The presence of an enzyme, p-dimethylaminobenzenediazo sodium sulfonate reductase, capable of reducing Dexon to N,N-dimethyl-p-phenylenediamine has been demonstrated in the cell-free extracts of the organism. The enzyme is found to be in the soluble fraction and requires dithiothreitol as a reductant.

1974 Applied microbiology

4. Experimental evaluation of Dexon suture in the dog. Full Text available with Trip Pro

Experimental evaluation of Dexon suture in the dog. 4413371 1974 12 16 2018 11 13 0027-9684 66 5 1974 Sep Journal of the National Medical Association J Natl Med Assoc Experimental evaluation of Dexon suture in the dog. 424-5 Aird C C CC Matory W F WF eng Comparative Study Journal Article United States J Natl Med Assoc 7503090 0027-9684 26009-03-0 Polyglycolic Acid IM Animals Dogs Evaluation Studies as Topic Inflammation Polyglycolic Acid Sutures Wound Healing 1974 9 1 1974 9 1 0 1 1974 9 1 0 0

1974 Journal of the National Medical Association

5. Skin closure with polyglycolic acid (Dexon). Full Text available with Trip Pro

Skin closure with polyglycolic acid (Dexon). Cosmetically satisfactory scars were achieved in 94.5% of skin crease orchidopexy wounds sutured with subcuticular polyglycolic acid. Of twenty-seven similar wounds closed with interrupted black silk sutures 18.5% developed hypertrophy at the medial end.

1978 Postgraduate medical journal

6. Wound closure with Dexon (polyglycolic acid) mass suture. Full Text available with Trip Pro

Wound closure with Dexon (polyglycolic acid) mass suture. A series of 814 consectuvie laparotomy incisions at three hospitals were closed with No 2 Dexon (polyglycolic acid) sutures using the 'near and far' technique. The incidence of wound dehiscence was 0.5%, of sinus formation 1%, and of incisional hernia 2.2% at 6 months and 6% at 3 years.

1978 Annals of the Royal College of Surgeons of England

7. Dexon versus chromic catgut-Mersilene simultaneously employed for gastro-intestinal anastomoses, evaluated endoscopically. (Abstract)

Dexon versus chromic catgut-Mersilene simultaneously employed for gastro-intestinal anastomoses, evaluated endoscopically. Twenty gastro-intestinal anastomoses were sutured, in a randomized manner, with two layers of Dexon in the anterior or posterior suture line, and chromic catgut-Merselene in the other. Each of the suture lines was evaluated "blind" using endoscopy, 3 months postoperatively. No anastomosis failure was observed, in any of the patients, nor were there any definite differences (...) between the two suture lines with regard to the degree of irritation. However, visible, non-absorbable suture material could be seen in two cases where conventional material had been employed. It is concluded that two layers of Dexon are preferable to non-absorbable materials for use in gastro-intestinal anastomoses.

1978 Acta chirurgica Scandinavica Controlled trial quality: uncertain

8. Hypertrophic scarring: Dexon suture in a randomized trial. (Abstract)

Hypertrophic scarring: Dexon suture in a randomized trial. In a randomized prospective trial of three methods of skin suture an increased incidence of hypertrophic scarring in paramedian and inguinal wounds has been found to be associated with the use of 2/0 Dexon suture subcuticularly. However, the variance associated with the type of suture was less than that associated with the sex of the patient. The patient's opinion of the appearance of the scar was the same for all three suture methods

1979 British Journal of Surgery Controlled trial quality: uncertain

9. Polyglycolic acid (Dexon) versus silk for fascial closure of abdominal incisions. (Abstract)

Polyglycolic acid (Dexon) versus silk for fascial closure of abdominal incisions. Suture-granulomas were previously found in 6% of patients subjected to colorectal surgery. It was therefore investigated whether the use of polyglycolic acid (Dexon) instead of silk for fascial closure of abdominal incisions would reduce the rate of granulomas without an accompanying increase in rate of wound dehiscences. The two sutures were evaluated in a triple blind, randomized trial, using the paired sample (...) at that time. Postoperative wound infections occurred in 7 patients after silk and 8 after polyglycolic acid. It is concluced that the use of polyglycolic acid (Dexon) nearly eliminates the risk of suture-granulomas, without increasing the risk of wound dehiscences; on the contrary, the rate of dehiscences was lower after polyglycolic acid.

1976 Acta chirurgica Scandinavica Controlled trial quality: uncertain

10. Comparative trial of Dexon (polyglycolic acid), collagen, and silk sutures in ophthalmic surgery. Full Text available with Trip Pro

Comparative trial of Dexon (polyglycolic acid), collagen, and silk sutures in ophthalmic surgery. The tissue reaction, absorption, and handling properties of Dexon synthetic absorbable sutures, which are made from polymerized hydroxyacetic acid, were compared with those of silk and collagen in 51 eye operations, consisting mainly of cataract extractions and squint corrections. There was no significant difference between the sutures as regards degree of tissue reaction. The Dexon sutures were (...) very strong and the knots held well. The sizes used in this series were found to be a little too thick and stiff for use in micro-surgery; smaller sizes would be easier to use and still remain strong enough. The Dexon was reliably absorbed in 5 weeks on average. No serious adverse reactions were seen with any of the sutures. Dexon was as well tolerated as the control sutures but had the advantage over silk of being absorbed and over collagen of containing no foreign protein.

1975 British Journal of Ophthalmology Controlled trial quality: uncertain

11. Dexon versus conventional sutures in hernia repair. (Abstract)

Dexon versus conventional sutures in hernia repair. An unselected study of 87 inguinal herniorrhapies was carried out over a 2-year period using polyglycolic acid (Dexon) sutures in 46 procedures and conventional sutures in the remaining 41. Tissue reaction was the same with both types of suture; however, the incidence of recurrence was lower with the use of conventional sutures. This study has not confirmed the superiority of Dexon sutures reported in other studies.

1976 Canadian journal of surgery. Journal canadien de chirurgie Controlled trial quality: uncertain

13. Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma

Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex Visumetazone Drug: Ixazomib Citrate Given PO Other Names: MLN-9708 MLN9708 Ninlaro Other: Laboratory Biomarker Analysis Correlative studies Biological: Pembrolizumab Given IV Other Names: Keytruda Lambrolizumab MK-3475 SCH 900475

2018 Clinical Trials

14. Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex Visumetazone Drug: Doxorubicin Hydrochloride Given IV Other Names: 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI) ADM Adriacin Adriamycin Adriamycin (...) : Aacidexam Adexone Aknichthol Dexa Alba-Dex Alin Alin Depot Alin Oftalmico Amplidermis Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin

2018 Clinical Trials

15. Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

: Aacidexam Adexone Aknichthol Dexa Alba-Dex Alin Alin Depot Alin Oftalmico Amplidermis Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin (...) Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone

2018 Clinical Trials

16. Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Names: Aacidexam Adexone Aknichthol Dexa Alba-Dex Alin Alin Depot Alin Oftalmico Amplidermis Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta

2018 Clinical Trials

17. Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex Visumetazone Drug: Ixazomib Citrate Given PO Other Names: MLN-9708 MLN9708 Ninlaro Other: Laboratory Biomarker Analysis

2018 Clinical Trials

18. Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Participants With Advanced, Metastatic, or Recurrent Cancer

Adexone Aknichthol Dexa Alba-Dex Alin Alin Depot Alin Oftalmico Amplidermis Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten

2018 Clinical Trials

19. Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex Visumetazone Drug: Ponatinib Hydrochloride Given PO Other Names: AP24534 HCl Iclusig Biological: Rituximab Given IV Other Names: ABP 798 BI 695500

2018 Clinical Trials

20. Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>